Literature DB >> 29630104

Early diagnostic role of PSA combined miR-155 detection in prostate cancer.

T Guo1, X-X Wang, H Fu, Y-C Tang, B-Q Meng, C-H Chen.   

Abstract

OBJECTIVE: As a kind of malignant tumor in the male genitourinary system, prostate cancer exhibits significantly increased occurrence. Prostate-specific antigen (PSA) expression can be seen in the prostate cancer, prostatitis, and other diseases, therefore, lack of diagnostic specificity. The miR-155 expression is abnormally increased in the tumors. Therefore, this study aims to explore the clinical significance of PSA combined miR-155 detection in the early diagnosis of prostate cancer. PATIENTS AND METHODS: A total of 86 patients diagnosed with prostate cancer were enrolled in this study. PSA and miR-155 gene expression in tumor tissue were detected by using Real-time PCR. The serum levels of PSA were measured by using enzyme-linked immunosorbent assay (ELISA). The correlation of PSA and miR-155 expression with age, body mass index (BMI), tumor volume, tumor-node-metastasis (TNM) stage, lymph node metastasis (LNM), and other clinicopathological features were analyzed, respectively.
RESULTS: Serum PSA expression and PSA gene in tumor tissue were significantly higher compared to that in adjacent tissues (p<0.05). PSA gene and protein increased significantly with the clinical stage of TNM and decreased following the increase of grade (p<0.05). The miR-155 level was significantly elevated in the tumor tissue compared with para-carcinoma tissue (p<0.05). PSA and miR-155 expressions were positively correlated with TNM stage, tumor volume, and LNM, and negatively correlated with grade (p<0.05).
CONCLUSIONS: PSA and miR-155 were closely related to the clinicopathological features of prostate cancer. Combined detection is helpful for the early diagnosis of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29630104     DOI: 10.26355/eurrev_201803_14568

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

Review 1.  Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma.

Authors:  Ane Larrabeiti-Etxebarria; Maria Lopez-Santillan; Borja Santos-Zorrozua; Elixabet Lopez-Lopez; Africa Garcia-Orad
Journal:  Cancers (Basel)       Date:  2019-01-26       Impact factor: 6.639

2.  Survival Analysis and a Novel Nomogram Model for Progression-Free Survival in Patients with Prostate Cancer.

Authors:  Yuefu Han; Xingqiao Wen; Dong Chen; Xiaojuan Li; Qu Leng; Yuehui Wen; Jun Li; Weian Zhu
Journal:  J Oncol       Date:  2022-03-22       Impact factor: 4.375

3.  Use of MicroRNAs as biomarkers in the early diagnosis of prostate cancer.

Authors:  Duran Canatan; Ozlem Yılmaz; Yonca Sonmez; Abdullah Cim; Mehmet Baykara; Murat Savas; Hasan Senol Coskun; Sema Sezgin Goksu; Mehmet Rıfkı Aktekin
Journal:  Acta Biomed       Date:  2022-07-01

4.  lncRNA HAND2-AS1 Regulates Prostate Cancer Cell Growth Through Targeting the miR-106a-5p/RBM24 Axis.

Authors:  Pengtao Wei; Jing Yang; Dandan Zhang; Meng Cui; Lianjun Li
Journal:  Onco Targets Ther       Date:  2020-05-21       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.